Landscape Capital Management L.L.C. acquired a new position in Certara, Inc. (NASDAQ:CERT – Get Rating) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,656 shares of the company’s stock, valued at approximately $155,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Geneva Capital Management LLC purchased a new position in shares of Certara in the third quarter worth approximately $15,541,000. Rice Hall James & Associates LLC bought a new stake in Certara during the 3rd quarter worth approximately $1,501,000. State of New Jersey Common Pension Fund D raised its stake in Certara by 24.9% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 143,257 shares of the company’s stock worth $1,902,000 after acquiring an additional 28,524 shares during the period. US Bancorp DE raised its position in shares of Certara by 11.7% during the third quarter. US Bancorp DE now owns 22,309 shares of the company’s stock valued at $297,000 after buying an additional 2,334 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Certara during the third quarter valued at approximately $95,000. Hedge funds and other institutional investors own 75.45% of the company’s stock.
Insider Activity at Certara
In related news, Director Matthew M. Walsh sold 12,059 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $14.74, for a total value of $177,749.66. Following the sale, the director now owns 167,901 shares in the company, valued at $2,474,860.74. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Matthew M. Walsh sold 12,059 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $14.74, for a total value of $177,749.66. Following the sale, the director now owns 167,901 shares in the company, valued at $2,474,860.74. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Leif E. Pedersen sold 51,223 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $15.55, for a total value of $796,517.65. Following the completion of the sale, the insider now owns 175,500 shares in the company, valued at approximately $2,729,025. The disclosure for this sale can be found here. Insiders have sold a total of 30,017,803 shares of company stock worth $450,292,082 over the last quarter. Insiders own 4.02% of the company’s stock.
Certara Stock Performance
Certara (NASDAQ:CERT – Get Rating) last posted its quarterly earnings data on Monday, November 7th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. Certara had a negative net margin of 1.28% and a positive return on equity of 4.25%. The firm had revenue of $84.70 million for the quarter, compared to the consensus estimate of $82.36 million. As a group, equities analysts anticipate that Certara, Inc. will post 0.29 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on CERT shares. Robert W. Baird cut shares of Certara from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $17.00 to $19.00 in a research report on Wednesday, December 14th. Credit Suisse Group reduced their price objective on shares of Certara from $22.00 to $20.00 and set an “outperform” rating on the stock in a research report on Monday, November 14th. Finally, Barclays reduced their price target on shares of Certara from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, October 6th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.43.
Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
- Get a free copy of the StockNews.com research report on Certara (CERT)
- UiPath is the Blue-Collar AI Platform to Watch in 2023
- Is Canadian Solar Too Hot to Handle?
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.